Evidence map›Paper›PMID 32362422›Full record

ArticlePathology, research and practice2020

EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy.

Chhavi Gupta, Akash Sali, Binyun Ma, Alexandra Jackovich, Sarmad Sadeghi, David Quinn, Parkash Gill, Inderbir Gill

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology, research and practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. EphrinB2: Expression of a novel potential target in renal cell carcinoma.Indian journal of urology : IJU : journal of the Urological Society of India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chhavi GuptaDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: drchhavi26@gmail.com.
Akash SaliDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Binyun MaDepartment of Medicine, USC Norris Comprehensive Cancer Centre, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Alexandra JackovichDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Medicine, USC Norris Comprehensive Cancer Centre, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Sarmad SadeghiDepartment of Medicine, USC Norris Comprehensive Cancer Centre, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
David QuinnDepartment of Medicine, USC Norris Comprehensive Cancer Centre, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Parkash GillDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Medicine, USC Norris Comprehensive Cancer Centre, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Inderbir GillDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

backgroundProstate cancer is managed by surgery, androgen deprivation and cytotoxic chemotherapy. Targeted therapy is emerging as an important pillar in cancer therapeutics, however, efficacy in prostate cancer has been limited. Eph-ephrin is a novel pathway that is upregulated in prostate cancer and promotes the initiation and progression of cancer. The aim of this study was to determine the immunohistochemical expression of ephrinB2 in prostate adenocarcinoma.

methodsA tissue microarray comprising of prostate adenocarcinoma of different grade groups was stained with a monoclonal anti-ephrinB2 antibody (Abcam, AB201512). The tumor and endothelial cells expressing the ephrinB2 positivity were noted. The statistical analysis was performed to determine the difference in expression based on grade groups and the TNM stage.

resultsEphrinB2 was expressed in 40 out of 72 cases (55.5 %) of prostate adenocarcinoma and was predominantly negative in the normal prostatic tissue. There was no significant difference in the expression of ephrinB2 in various grade groups (p = 0.7) or stages (p = 0.6).

conclusionsEphrinB2 is expressed in a significant number of prostate adenocarcinoma regardless of grade and stage. Hence, there is a potential to target this molecule in the low-grade tumors with localized disease as well as high grade, high volume tumors with metastatic disease.

Indexed as

AdenocarcinomaBiomarkers, TumorEphrin-B2HumansMaleMolecular Targeted TherapyProstatic NeoplasmsBiomarkers, TumorEphrin-B2Eph-ephrinEphrinB2ImmunohistochemistryProstate adenocarcinomaTargeted therapy

Identifiers

PMID32362422
PMCPMC9084634

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.